Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Damon Runyon identifies scientists with the highest potential to revolutionize how we prevent, diagnose, and treat all forms of cancer.
A new technique called CopyKAT can identify genetic abnormalities linked to cancer in a single cell.
Researchers have identified another molecule that may lead to the development of more effective targeted medications.
Experimental monoclonal antibody sotigalimab shows promising results in a Phase I study.
The Damon Runyon Cancer Research Foundation awards $2.8 million to innovative early career scientists.
Damon Runyon Cancer Research Foundation shares some exciting discoveries made by Damon Runyon researchers in 2020.
Damon Runyon researchers are making an impact through understanding the biology and developing novel treatments.
Some patients develop a secondary blood cancer after receiving radiation or chemotherapy treatment for their initial cancer diagnosis
Scientists studied the drug, BO-112, using lab dish experiments and a mouse model of melanoma.
Scientists studied how a series of stepwise mutations in normal blood cells could trigger the transformation to cancer.
After being diagnosed with acute lymphoblastic leukemia, 7 year-old Ryan was officially declared in remission in April 2019.
Results revealed vast cellular diversity in both lung tumors and the tissue surrounding the tumor.
Results appear on an easy-to-read strip that is akin to a pregnancy test, without the need for expensive or specialized lab equipment.
Scientists develop a platform to study early-stage lung cancer and to identify potential new treatments.
Some scientists are investigating how the virus enters humans cells, developing more efficient testing and searching for treatments.
Researchers discover that a molecule that helps cancer cells spread is found at higher levels in otherwise healthy people over 60.
The drug was associated with a 19% and 22% higher risk of being diagnosed with cancer that spread and advanced cancer, respectively.
Elevated levels of a protein called RUNX2 in human lung tumors predict a worse prognosis.
Grants totaling nearly $3.5 million give early career investigators independence to pursue brave and bold cancer research.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.